Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy; Department of Mental Health, Local Health Authority Viterbo, Viterbo, Italy.
Department of Surgery, M.G. General Vannini Hospital, Istituto Figlie Di San Camillo, Rome, Italy.
Drug Alcohol Depend. 2024 Nov 1;264:112424. doi: 10.1016/j.drugalcdep.2024.112424. Epub 2024 Sep 7.
Increasing evidence suggests that GLP-1 receptor agonists (GLP-1RA) have a potential use in addiction treatment. Few studies have assessed the impact of GLP-1RA on substance use disorder (SUD), particularly in humans. The study aimed to do systematic review of clinical trials to assess GLP-1RA's effect on reducing SUD in patients.
The scientific literature was reviewed using the MEDLINE, Scopus and Cochrane Library databases, following PRISMA guidelines. Studies including patients with a diagnosis of SU who were treated with GLP-1RA were selected. The primary outcome was GLP-1RA's therapeutic effect on SUD, and the secondary outcomes were therapeutic effects of GLP-1RA on weight, BMI and HbA1c.
1218 studies were retrieved, resulting in 507 papers after title and abstract screening. Following full-text review, only 5 articles met inclusion criteria. We incorporated a total of 630 participants utilizing Exenatide (n=3) and Dulaglutide (n=2) as GLP-1RAs. Therapeutic effect of GLP-1RA on SUD was assessed in 5 studies, with 3 demonstrating a significant decrease in SUD (alcohol and nicotine). GLP-1RA's impact on body weight, BMI, and HbA1c, was reported in 3 studies. These revealed a notable reduction in these parameters among the GLP-1RA treated group.
This review will give an overview of current new findings in human studies; we suggest that the effects of GLP-1RA in SUD is a possible new option of therapy in addiction medicine.
越来越多的证据表明，GLP-1 受体激动剂（GLP-1RA）在治疗成瘾方面具有潜在用途。很少有研究评估 GLP-1RA 对物质使用障碍（SUD）的影响，特别是在人类中。本研究旨在对评估 GLP-1RA 减少 SUD 患者 SUD 的临床试验进行系统评价。
根据 PRISMA 指南，使用 MEDLINE、Scopus 和 Cochrane Library 数据库对科学文献进行了回顾。选择了包括被诊断为 SUD 并接受 GLP-1RA 治疗的患者的研究。主要结局是 GLP-1RA 对 SUD 的治疗效果，次要结局是 GLP-1RA 对体重、BMI 和 HbA1c 的治疗效果。
共检索到 1218 项研究，经标题和摘要筛选后得到 507 篇论文。经过全文审查，只有 5 篇文章符合纳入标准。我们共纳入了 630 名使用 Exenatide（n=3）和 Dulaglutide（n=2）作为 GLP-1RA 的参与者。5 项研究评估了 GLP-1RA 对 SUD 的治疗效果，其中 3 项研究表明 SUD（酒精和尼古丁）显著下降。3 项研究报告了 GLP-1RA 对体重、BMI 和 HbA1c 的影响，结果显示 GLP-1RA 治疗组这些参数显著降低。
本综述将概述人类研究中的最新发现；我们认为 GLP-1RA 在 SUD 中的作用可能是成瘾医学治疗的一种新选择。
